医学部 脳神経外科学
基本情報
研究分野
1経歴
10-
2025年4月 - 現在
-
2022年4月 - 2025年3月
-
2021年4月 - 2022年3月
-
2020年12月 - 2021年3月
-
2019年4月 - 2020年11月
受賞
2-
2020年9月
-
2015年3月
論文
27-
Scientific reports 15(1) 1750-1750 2025年1月11日Karnofsky Performance Status (KPS) is a widely used scale to assess performance status. KPS ≥ 50% implies that patients can live at home. Therefore, maintaining KPS ≥ 50% is important to improve the quality of life of patients with glioblastoma, whose median survival is less than 2 years. This study aimed to identify the factors associated with survival time with maintenance of KPS ≥ 50% (survival with KPS ≥ 50%) in patients with glioblastoma, IDH-wildtype. Ninety-eight patients with glioblastomas, IDH-wildtype, who were treated with concomitant radiotherapy (RT) and temozolomide (TMZ) followed by maintenance TMZ therapy, and whose KPS at the start of RT was ≥ 50%, were included. The median survival with KPS ≥ 50% was 13.3 months. In univariate analysis, preoperative KPS (≥ 80%), KPS at the start of RT (≥ 80%), residual tumor size (< 2 cm3), methylated MGMT promotor, and implantation of BCNU wafer were associated with survival with KPS ≥ 50%. In multivariate analysis, KPS at the start of RT (≥ 80%), methylated MGMT promotor, and residual tumor size (< 2 cm3) were significantly associated with increased survival with KPS ≥ 50%. A strategy of maximum possible tumor resection without compromising KPS is desirable to prolong the survival time with KPS ≥ 50%.
-
脳卒中 46(5) 380-385 2024年3月 査読有り筆頭著者責任著者
-
Radiology Case Reports 19(5) 1692-1696 2024年2月 査読有り筆頭著者